|Cancer Stem Cell News 6.36 September 13, 2017|
The authors describe an orally available, selective and potent KDM4 inhibitor with unique preclinical characteristics. To assess the anti-tumor properties of QC6352, they established a method to isolate and propagate breast cancer stem-like cells from individual triple-negative tumors resected from patients after neoadjuvant chemotherapy. [Cancer Res]
The authors identified CD109, a glycosylphosphatidylinositol- anchored protein and regulator of multiple signalling pathways, as a critical regulator of the progression of lower-grade glioma by clinicopathological and whole genome sequencing analysis of tissues from human glioma. The importance of CD109-positive perivascular tumor cells was confirmed not only in human lower-grade glioma tissues, but also in a mouse model that recapitulated human glioma. [J Pathol]
Glioblastoma (GBM) contains a cell hierarchy driven by stem-like cells (GSCs), responsible for tumor generation, therapeutic resistance and relapse. Researchers analyzed the mutational profile of GSCs isolated from either human primary GBMs (primary GSCs) or their matched tumors recurring after surgery and chemo-radiotherapy (recurrent GSCs). They found that recurrent GSCs can accumulate temozolomide-related mutations over primary GSCs, following both linear and branched patterns. [Stem Cells]
The authors modulated the expression of LGR5 using an overexpression vector or short hairpin RNA in cervical cancer cell lines. They demonstrated that elevated LGR5 expression in cervical cancer cells increased tumorsphere-forming efficiency; conferred chemoresistance to cisplatin treatment; augmented cell migration, invasion and clonogenicity; and elevated the levels of stem cell-related transcription factors in vitro. [Cell Death Dis]
Researchers examined ICG-001 and its potential role as a therapeutic in gastric cancer. The gastric cancer cell lines SGC-7901, MGC-803, BGC-823 and MKN-45 were used in vitro and in vivo. The abilities of cell proliferation, tumor sphere formation, metastasis, tumorgenesis and chemoresistance to chemotherapy drugs in vitro were evaluated by MTT assay, colony formation assay, flow cytometry, migration and invasion assay, and tumor spheres culture. [J Exp Clin Cancer Res]
Scientists examined the molecular mechanisms by which SATB2 induced malignant transformation of colorectal epithelial cells. SATB2 induced malignant transformation and these transformed cells gained the characteristics of CSCs by expressing stem cell markers and transcription factors. [Sci Rep]
Investigators examined the influence of sorafenib, a multiple-receptor tyrosine kinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma, on EpCAM+ and CD90+ cancer stem cells. CD90+ cells showed higher c-Kit gene/protein expression than EpCAM+ cells. [Sci Rep]
Researchers investigated the antitumor effect of GD55 on prostate CSC-like cells in vitro and in vivo. Prostate CSC-like sphere cells were acquired and enriched by culturing DU145, LNCap or P3 prostate cancer cells in suspension. [Acta Pharmacol Sin]
The authors aimed to investigate whether interleukin-6 (IL-6) knockdown may enhance the efficacy of cisplatin in laryngeal cancer stem cells and the potential involvement of the signal transducer and activator of transcription 3 and hypoxia-inducible factor 1 (HIF1) in this effect. [Cancer Cell Int]
The authors describe nasal anatomy, routes of stem cell migration, and factors affecting stem cell delivery to hard-to-reach tumors. They discuss the molecular mechanisms underlying stem cell migration following delivery, as well as possible stem cell effector functions to be considered in combination with intranasal delivery. [Expert Opin Drug Deliv]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Sandoz announced that the FDA has accepted its Biologics License Application under the 351 (k) pathway for a proposed biosimilar to the reference medicine, Rituxan®†. [Sandoz]
DelMar Pharmaceuticals announced the initiation of a Phase II clinical trial for its lead agent VAL-083 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as an alternative to standard-of-care temozolomide in patients with MGMT-unmethylated GBM. [DelMar Pharmaceuticals]
A program that grades UK universities on gender equality in science is going global. Versions of the rating scheme have started up in the past two years in Australia and Ireland, and a small-scale pilot begins next month in the United States. [Nature News]
More than a decade after a fraud scandal in stem cell science rocked South Korea, scientists in the field are ramping up pressure on the government to relax the country’s strict regulations on human-embryo research — which many researchers label a ban. The nation’s bioethics committee held a public forum with the Ministry of Health and Welfare in Seoul, inviting 11 researchers and scholars to discuss possible changes to the country’s bioethics policies on research. [Nature News]
Congress has not only rejected the president’s National Institutes of Health proposal; lawmakers from both parties have joined forces to increase spending on biomedical research — and have bragged about it. [The New York Times]
NEW 11th European Breast Cancer Conference (EBCC-11)
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.